Efficacy of Percutaneous Injection of Triamcinolone in the Treatment of Mammillary Fistula
NCT ID: NCT01315080
Last Updated: 2011-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
10 participants
OBSERVATIONAL
2011-03-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Intralesional Triamcinolone Injection With Whole Breast Detection Radical Surgery
NCT05281419
Medical and Surgical Treatment for Idiopathic Granulomatous Mastitis
NCT02959580
Could Intralesional Steroid be the Novel Treatment for Granulomatous Mastitis?
NCT04596046
Effectiveness of Stellate Ganglion Block in Breast Cancer Related Lymphedema
NCT04165512
Idiopathic Granulomatous Mastitis Combination Therapy
NCT05361629
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. patients with MF treated by percutaneous drainage and saline solution.
2. patients with MF treated by percutaneous drainage and saline solution plus percutaneous triamcinolone.
These patients are treated following usual clinical practice in our Department. All the procedures are made through an ultrasound-guided way. During the follow-up of these cases (clinical and with ultrasound) resolution rate will be registered by the same investigator.
The follow-up will be at least 6 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Saline
Percutaneous drainage and saline solution irrigation
No interventions assigned to this group
Triamcinolone
Percutaneous drainage and saline solution irrigation plus percutaneous triamcinolone
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* older than 18 years
* patient acceptation to the recruitment
Exclusion Criteria
* arterial hypertension
* immunodepression
* peptic ulcer
* chronic bowel inflammatory diseases
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Universitario Virgen de la Arrixaca
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Virgen de la Arrixaca University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juan D Berna, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Virgen de la Arrixaca University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Virgen de la Arrixaca University Hospital
Murcia, Murcia, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FISTULA001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.